Plans to seek FDA submission and approval for first-in-human trials in type 1 diabetes and stiff person syndrome targeted for early 2026 MOUNTAIN VIEW, Calif., August 25, 2025--(BUSINESS WIRE)--Aditxt ...
USC scientists have surmounted a big roadblock in regenerative medicine that has so far constrained the ability to use repurposed cells to treat diseases. The researchers figured out how to reprogram ...
By combining DNA instructions with our proprietary delivery platform, we are aiming for digital-like precision in how the immune system is retrained. With the first ADI product candidate ADI-100, we ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results